Inoviv

Inoviv operates as a specialized preclinical CRO, leveraging its expertise in in vivo models to de-risk drug development for its clients. Founded in 2012 and based in the Cambridge biotech cluster, the company has established itself as a partner for biopharma companies needing robust proof-of-concept data. Its business model is service-based, generating revenue through contracted research projects. The company's success is tied to the broader R&D outsourcing trend and the continuous demand for high-quality preclinical data to secure funding and regulatory approval.

Integrated suite of in vivo pharmacology and efficacy models, including specialized animal models for oncology (e.g., PDX, orthotopic), immunology, and neuroscience, supported by in vivo imaging and biomarker analysis.

Inoviv competes in the fragmented preclinical CRO market. It faces competition from large, full-service global players (e.g., Charles River Laboratories, Labcorp) that offer scale and a broad service portfolio, and from many other small, specialized CROs focusing on specific therapeutic areas or model types. Differentiation is based on scientific reputation, model quality, client service, and geographic proximity.